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Abstract 
The Effects of Linoleic Acid on Rubidium Uptake by Sodium Potassium Pumps in 
Rat Myocardial Cells 
Name: Mohammed Gaafarelkhalifa 
Degree: Master of Biology 
Institution: Minnesota State University, Mankato 
Date of Submission: November 9th, 2017 
 Congestive Heart failure is amongst the leading causes of death in the United 
States. It is treated through a variety of different therapeutic targets including the 
inhibition of sodium potassium pumps. Drugs currently used in this pathway of treatment 
such as Digitalis have adverse toxic effects. This study examines the inhibitory effects of 
linoleic acid (L.A) on sodium potassium pumps in isolated rat cardiomyocytes using the 
incorporation of rubidium detected by SEM/EDS technology as the index for sodium-
potassium pump activity. Isolated heart cells were incubated in the following treatments: 
Rb-Krebs buffer without treatment (negative control), Ouabain+ Rb-Krebs buffer 
(positive control), 10-3 M L.A+ Rb-Krebs buffer, and 10-6 M L.A+ Rb-Krebs buffer. The 
results established Rb-Krebs as the negative control with a mean of 1.279 +/- 0.075 for 
Rb % average of 10 replicates with 10 cells analyzed in each replicate. Ouabain + Rb-
Krebs was established as the positive control for inhibition of rubidium uptake with a 
mean value of 0.701 +/- 0.073. It was found that the 10-6 M, and not 10-3 M, 
concentration of linoleic acid exhibited inhibitory effects of rubidium uptake with a mean 
value of 0.805 +/- 0.121 and 0.903 +/- 0.095, respectively. 
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Introduction 
 The sodium potassium ATPase, also known as the sodium potassium pump, is a 
cellular membrane protein located in all animal cells (2). Its main function is to transport 
potassium ions into the cell and to transport sodium ions out against their respective 
concentration gradients. This action serves the cell directly in several ways such as 
maintenance of cell volume, allowing the cells to create a cellular membrane resting 
potential, and serving as a transducer for cellular signals (2). Indirectly, functions of the 
sodium potassium pump include interactions which couple its activity with specialized 
cellular processes. One such interaction couples the pump’s activity with the sodium-
calcium exchange (NCX) channel (2). Calcium ions are necessary for cardiomyocytes 
(heart muscle cells) to generate heart muscle contractions (10).    
 Inhibition of sodium potassium pump activity has been a treatment route for 
congestive heart failure (CHF) (10). This inhibition requires specific molecules such as 
glycosides (23), for example digoxins and Ouabain, which have been used as prescription 
medicine and home remedies, respectively, to treat heart failure and other heart problems 
for over 200 years (10). The therapeutic dose range for digoxins, pharmaceutically 
recognized as digitalis, is narrow, falling between 0.8 -1.8 ng/ml of blood (19). CHF 
patients under digoxin treatment face issues of drug toxicity. Moreover, digoxins may 
exhibit drug-to-drug interactions with drugs that relieve symptoms and complications of 
CHF (8). Such drugs include diuretics used to relieve fluid retention and may exacerbate 
digoxin toxicity. Symptoms of digoxin toxicity include gastrointestinal complications, 
arrhythmias, and breathing difficulty amongst many other severe symptoms (23).  
Linoleic acid is a naturally occurring fatty acid derived from several plants 
including Nigella sativa. Nigella sativa has been a staple of traditional medicine for 
centuries (1). Often ingested orally, the seeds of Nigella sativa are used to alleviate a 
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variety of different aliments including respiratory infections and hypertension (1). Early 
studies suggest that linoleic acid inhibits sodium potassium pumps (12, 25). 
Toxicologically, linoleic acid appears to be safe for human consumption, and is included 
in a variety of dietary supplements (27). It exhibits no apparent toxic effects in doses as 
high as 3.2 grams of linoleic acid per kilogram of body mass. However, it is important to 
note that linoleic acid has a variety of chemically produced isomers and metabolic 
derivatives, some of which have toxic effects (27). The most biologically-active linoleic 
acid isomers, cis-9,trans-11 and trans-10,cis-12 isomers, are considered safer for human 
consumption (30) and are used in this study. 
The hypothesis of this thesis is that linoleic acid decreases sodium potassium 
pump activity. The pump activity was determined by cardiomyocyte rubidium weight 
percentages. Rubidium is a congener for potassium and is actively transported into heart 
muscle cells by sodium potassium ATPase (18, 21). Furthermore, cardiomyocyte 
rubidium weight percent may be measured by Scanning Electron Microscopy (SEM) and 
Energy Dispersive Spectroscopy (EDS) (4, 18, 21).    
  There were four main experimental objectives in this thesis. First, isolation of 
viable adult rat cardiomyocytes by the digestive enzyme collagenase was optimized 
through preliminary trials. Second, cardiomyocyte rubidium weight percent over time 
was determined by using Scanning Electron Microscopy (SEM) and Energy Dispersive 
Spectroscopy (EDS). Third, inhibitory effect of Ouabain on rubidium uptake was 
determined by a decrease in cardiomyocyte rubidium weight percentages through SEM 
and EDS analysis. Finally, the effect of linoleic acid on cardiomyocyte rubidium weight 
percent was determined. 
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Literature Review 
Congestive Heart Failure 
 Congestive heart failure, CHF, is a cardiovascular condition where the heart 
ventricles are not able to adequately pump blood due to cardiac tissue damage, 
restrictions in coronary flow, or any conditions resulting in the mechanical dysfunction of 
the cardiac pump (26). Heart failure could occur during both of the major stages of the 
cardiac cycle, cardiac systole and cardiac diastole (26). Failure during cardiac systole 
causes insufficient contraction resulting in decreased ejection fraction, or the fraction of 
stroke volume divided by end diastolic volume (26). Diastolic heart failure, on the other 
hand, is the inability of the ventricle to relax or dilate sufficiently to accommodate for 
proper cardiac filling resulting in a decreased end diastolic volume (EDV), which in turn 
decreases the overall cardiac output (26). 
 Heart failure often occurs in one side of the heart so that the failed side increases 
the workload and demands of the still healthy side, which eventually leads to its failure 
(26). Right-sided heart failure results in the right ventricle being unable to generate 
forceful enough contractions to pump the blood it receives from the systemic (body) 
circulation via the right atrium (26). As a result, there is a backup of fluids and elevated 
venous pressure, causing fluid retention in organs, bodily fatigue and edema (26). Left-
sided heart failure results in the left ventricle being unable to pump the blood it receives 
from the pulmonary circulation via the left atrium (26). As a result, hydrostatic pressure 
in pulmonary capillary beds is elevated, causing vascular fluid leakage into pulmonary 
tissues (26). In either-sided heart failure, the progression of the disease is difficult for the 
patients as they struggle to perform basic functions and movements. The heart is unable 
to keep up with the increasing demand, and depending on the overall level of fitness and 
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health of the patient, intrinsic and extrinsic factors may further compound the severity of 
congestive heart failure symptoms (26). 
 Today, and with the increase in age span and the emergence of age related 
diseases, heart disease is at the top of the charts as the number one leading cause of death 
in the United States (11). In 2010, the American Heart Association reported that 5.1 
million individuals were diagnosed as CHF patients in the United States (11). Half of 
CHF patients die within five years of diagnosis (11). In 2009, Centers for Disease Control 
(CDC) reported that one out of every nine deaths had CHF as the main or contributing 
cause of death (11). Treatment of CHF in the United States costs an approximate $32 
billion each year (19). 
 There are two main treatment avenues for patients with CHF: 1) life style 
changes, and 2) pharmaceuticals. Physicians often promote life style changes as the main 
mode of treatment and first line of defense against CHF. Those lifestyle changes include 
cessation of smoking, drug use, and ethanol consumption (34). Individuals are also put on 
a carful diet and an exercise regimen to rehabilitate their cardiovascular system. Studies 
have shown that these changes lead to gradual but significant improvement in cardiac 
function (34). The success of such program depends on the extent and stage of the heart 
failure, but also it depends and the compliance and willingness of the patients to conform 
to the program. Unfortunately, patients often revert to their old lifestyles after a brief 
period of change (34). That complicates their recovery process and renders the heart 
failing once again. Medical doctors then introduce the more aggressive form of treatment, 
pharmaceuticals. 
 There are three main classes of pharmaceuticals used for treating CHF: 
vasodilators, diuretics, and sodium potassium pump inhibitors (29). Vasodilators are 
compounds that widen blood vessels throughout the body (26). They relieve CHF by 
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widening coronary arteries to enhance cardiac function by distributing oxygen rich blood 
to heart tissue, and by widening systemic and pulmonary arteries and reducing the 
workload on heart muscle (26). A second class of pharmaceuticals used to treat CHF is 
diuretics. This class of pharmaceuticals increases the excretion rate of bodily fluids 
through urine, relieving patients of edema and retained fluids in organs, including the 
congestion of lungs (29). A third class of pharmaceuticals is sodium potassium pump 
inhibitors. This thesis will focus on the inhibition of the sodium-potassium pump and will 
provide the rationale for proposing linoleic acid as an inhibitor of the pump. 
 
Sodium Potassium Pump 
 The sodium potassium adenosine triphosphatase, commonly referred to as the 
sodium potassium pump, is a transmembrane protein with one end of the protein exposed 
to the extracellular side and the other end is projected into the cell interior (2). The 
composition of the pump varies among specialized cells and among species. The most 
conserved components or protein domains are the α-subunit and β-subunit, but there are 
several isoforms of these subunits (10). The α-subunit serves as the binding site for the 
various molecules interacting with the pump including ATP, and it carries catalytic 
functions. The β-subunit spans across the membrane and it contains amino acid residues 
providing stability to the channel within the hydrophobic inners of the lipid bilayer (10).  
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Figure 1: A diagram showing the structure of sodium potassium ATPase.  Obtained from 
(http://www.mun.ca/biology/desmid/brian/BIOL2060/BIOL2060-07-08/08_11.jpg) 
 
 The sodium potassium pump (Figure 1) works in cycles including conformational 
changes of the pump, binding and release of phosphate groups, sodium, and potassium 
ions. In its original conformation, the pump has a sodium-binding site exposed 
intracellularly (2). Once three sodium ions bind, an adenosine triphosphate (ATP) is 
recruited at the α-subunit’s catalytic site where the energetic phosphate group is cleaved 
off and linked to the pump (2). The remaining adenosine diphosphate (ADP) is released. 
The energy harnessed from the energetic phosphate linkage drives a conformational 
change of the pump where the sodium-binding site is now exposed to the extracellular 
matrix, and the sodium ions are ejected out of the cell (2). At this conformation, the 
potassium binding site is exposed extracellularly. This conformation is also known as the 
E2P conformation of sodium potassium pumps. At this stage of the cycle, two potassium 
ions bind, which causes the release of the linked phosphate group (2). The release of the 
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phosphate group allows the pump to return to its original conformation, and thus 
exposing the potassium-binding site intracellularly (2). Potassium ions are released, and 
sodium ions are recruited to restart the cycle once again. The entirety of the cycle occurs 
in 10 milliseconds of time (2). The activity of sodium potassium pumps allows the cell to 
maintain a gradient of Na+ and K+ ions in both the extracellular and intracellular vicinity 
of a cellular membrane. This gradient of ions serves many functions including regulating 
osmotic pressure (or pressure created by water molecules) inside the cell, and by 
influencing the activity of other membrane channels or pumps (2). For example, 
extracellular Na+ ions drive the removal of excess intracellular calcium ions through the 
sodium calcium exchange (NCX) channel (28). 
 
Calcium and Muscle Cell Contraction 
 Calcium ions bind to many cellular proteins and affect their shape and functions, 
and therefore, intracellular calcium levels are highly regulated. For example, calcium is a 
major component in the excitation-contraction coupling pathway, as seen in 
cardiomyocytes (26). This pathway describes the movement of an action potential 
between neighboring cardiomyocytes, and the release of calcium from the sarcoplasmic 
reticulum of an excited cell into its intracellular space to develop a contraction (26). As 
part of this pathway, a relatively small amount of Ca2+ ions rush into a cardiomyocyte 
through T tubules in the cellular membrane. Once inside a cardiomyocyte, the calcium 
ions trigger the release of a much larger concentration of calcium ions from the 
sarcoplasmic reticulum (SR) (26). Calcium is actively pumped into the SR during 
refractory periods, periods in which the cardiac muscle is non-responsive to electrical 
stimuli and is not contracting (10). Once released from the SR onto the cytoplasm, 
calcium binds and activates proteins responsible for contracting a cell (26). Increases in 
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the number of calcium ions binding proteins responsible for contracting a cell leads to the 
development of more forceful cardiac contractions. Since the process of heart contraction 
is highly sensitive and rhythmic, cardiac cells naturally work to maintain lower 
concentration of free cytoplasmic calcium. Notably, the sodium-potassium pump couples 
its activity with NCX is a key regulatory measure for the removal of free cytoplasmic 
calcium (28).  
 
Glycosides and Enzymatic Inhibition  
 Enzyme inhibition is the process where a molecule, not the usual substrate, binds 
the enzyme in a manner that renders the enzyme unable to carry out its enzymatic 
function. In the case of sodium potassium pumps, inhibition stops the pump from moving 
potassium into the cell and sodium out of it (2). In myocardial sodium potassium pumps, 
such inhibition leads to a decreased concentration gradient for sodium to move into the 
cell (Figure 2). This inhibition also decreases NCX activity, and decreases removal rate 
of cytoplasmic calcium to the extracellular matrix (10). Therefore, when the sodium 
potassium pump is inhibited and intracellular calcium levels rise, more forceful cardiac 
contractions are generated (10). This coupled inhibition and increased number of calcium 
ions provides the basis for treatment of CHF by inducing more forceful heart contractions 
and increase overall cardiac output.  
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Figure 2: Digitalis mechanism of action where A) digitalis binds sodium-potassium pump, B) 
sodium-calcium exchange channel utilizes extracellular sodium pumped by sodium-potassium 
pumps to drive calcium out of the cell, C) decreased extracellular sodium due to inhibition of 
sodium-potassium pump by digitalis causes increase in free calcium that binds relaxed sarcomere, 
and D) calcium binding of sarcomere causes contraction. Obtained from 
(https://quizlet.com/24869073/dit-cardiovascular-1-11-flash-cards/). 
 
 
 Glycosides, such as Ouabain and digoxins, are one class of sodium potassium 
pump inhibitors. They are aromatic chains of molecules containing a carboxyl terminal 
end (Figure 3) (22). Digoxin as a compound has a molecular mass of 780.9, and Ouabain 
has a molecular mass of 728.77 (22). These two inhibitor molecules have many 
similarities both in their chemical and physical make-up. They both inhibit the binding of 
potassium and lock the sodium potassium pump at the E2P conformation (2).  
 
Linoleic Acid as an Inhibitor  
Nigella sativa, also known as “the black seed” (Figure 4), has been widely and 
historically used as a remedy for a variety of ailments ranging from respiratory infections 
15 
 
to cardiovascular conditions such as hypertension and what is now diagnosed as CHF (1, 
27). One active constituent of the seed appears to be linoleic acid (25). Loregeril et. al 
showed a significant decrease in the reoccurrence of myocardial infarction (MI) in 
survivors undergoing a Mediterranean diet rich in linoleic acid compared to survivors not 
on the diet (24). Linoleic acid is an 18 carbon conjugated fatty acid chain, meaning it has 
a stretch of alternating single and double bonds (Figure 3) (22). This conjugation allows 
the formation of isomers of the compound associated with the double bonds. Linoleic 
acid is an essential fatty acid that is metabolized into many biologically-active isomers 
involved in diverse range of physiological and pathological pathways (24). Linoleic acid 
metabolites are chemical derivatives containing one or multiple chemical groups added to 
the hydrocarbon chain or directly interacting with the carboxylic acid group (22). These 
derivatives exhibit varying conformational shapes, reactivity, and interactions with other 
molecules. For example, linoleic acid is a precursor in the formation of prostaglandins, 
and leukotrienes. Two of the most biologically-active linoleic isomers are the cis-9,trans-
11 and trans-10,cis-12 (30). The linoleic acid used in this thesis was a mixture of these 
isomers.   
 Dietary levels of linoleic acid isomers are around 15-174 mg daily, primarily from 
meats and oils (24). Pharmacological studies have shown that dietary supplements of 
linoleic acid at doses between 1.8 g – 7 g is safe for human consumption and may help in 
fat loss and in reduction of blood pressure. However, additional benefits were not 
observed in doses above 3.4 (24).    
Linoleic acid appears to interact with sodium potassium pumps. Mixtures of 
compounds extracted from Nigella sativa were used to determine their effect on sodium 
potassium pumps in pig kidney cells. The results indicated that there were two primary 
active constituents isolated from Nigella sativa that had inhibitory effects on sodium 
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pumps. Those two active constituents were oleic acid and linoleic acid (25). Ha et al. 
found that linoleic acid metabolites incorporated into the lipid bilayer and disrupted 
membrane fluidity (12). Their study found that the metabolites inhibited the sodium 
potassium pump.  However, it was unclear whether the disruption of membrane fluidity 
was the single cause of the sodium potassium pump inhibition (12). 
 
Figure 3: Chemical structures and molecular weight for Ouabain, Digoxin, and Linoleic Acid. 
Information in this figure is obtained from PubChem. 
 
 
 
Figure 4: Nigella sativa plant (left panel), and the black seeds from the plant (right panel).  
Obtained from ( https://www.gardenershq.com/flowerimage/Nigella-Sativa.jpg) and 
(http://changmoh.com/wp-content/uploads/2013/05/black_seed_healing-1.jpg)  
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Rubidium as a Potassium Congener   
 The element rubidium is an alkali metal of the first group within the periodic table 
(33). It lies a single period beneath potassium, and exhibits similar chemical properties 
and interactions. Potassium has an atomic mass of 39.09, an atomic radius of 235 
picometer (pm), and atomic volume of 45.3 cubic centimeter per mole (cc/mol). 
Rubidium has an atomic mass of 85.46, an atomic radius of 248 pm, and an atomic 
volume of 55.9 cc/mol (33). Because rubidium is similar to potassium, is not normally 
found in the cell, and does not appear to have a harmful effect, it has been used as a tracer 
for potassium uptake into tissue via sodium potassium pump activity (4, 18, 21). 
Kupriyanov et al. used magnetic resonance imaging to determine the uptake of 87Rb by 
pig hearts (21).  Beck et al. infused rubidium chloride into kidney tissue and then used 
energy dispersive x-ray spectroscopy (EDS) to measure the incorporation of rubidium 
into kidney cells (4). Kalinowski infused rubidium in vivo into rats and subsequently used 
EDS to determine rubidium uptake in freeze dried rat muscles, hearts, and kidneys (18).   
 
Langendorff Apparatus 
 The Langendorff apparatus provides a means to maintain viability of an excised 
heart (5). The basic Langendorff apparatus provides a means to infuse an oxygenated 
physiological solution into the coronary vasculature of the heart while maintaining 
temperature, and pressure. Solutions infused into the isolated heart are delivered through 
an aortic cannula inserted retrograde so that its tip is situated at the ostia of the coronary 
arteries (5). The retrograde infusion closes the aortic semilunar valve so that the perfusate 
flows into the coronary arteries (5). 
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Principles of Scanning Electron Microscopy 
 The scanning electron microscope is used to obtain surface views of cells and 
tissues utilizing electrons to create an image (15). This technology is based on the 
principle that a high energy, focused electron beam interacts with the object to cause a 
variety of emissions as illustrated in Figure 5 (15). The scanning electron microscope 
(SEM) includes an electron gun, which is directed towards the sample. The electron 
beam, generated from the electron gun is focused on the sample by magnetic lenses as 
illustrated in Figure 6. As the electron beam excites the sample, secondary electrons are 
emitted from the surface of the sample. A detector gathers secondary electrons emitted by 
the excited sample (15). The signal from the detector is amplified and is converted into 
gray-scale values and displayed as an image on a monitor in synchrony with the scanning 
electron beam (15). In addition to electron emission, x-rays are also emitted from the 
sample and can be detected by energy dispersive spectroscopy (EDS) (15, 17).  
  
Figure 5:  Types of emissions from a specimen excited by incident electron beam.  Obtained 
from (http://ehs.virginia.edu/ehs/ehs.rs/rs.images/sem.incident.beam.coutesy.iowa.state.jpg). 
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Figure 6: Components of a Scanning Electron Microscope. Obtained from (31). 
 
Principles of Energy Dispersive Spectroscopy (EDS) 
With EDS, the energy levels of the emitted x-ray photons are characteristic of the 
chemical elements in the excited sample. The emitted x-ray photons are counted 
electronically and categorized at each energy level as seen in Figure 7.  Information 
about the chemical elements present in the sample is determined by x-ray photon counts 
at the characteristic spectral energy peaks of the elements.  Additionally, the x-ray photon 
counts in the characteristic spectral peaks in relation to background counts provide a 
means to determine the percent of the element present in the mass excited by the electron 
beam (Figure 8).  Finally, because x-rays are emitted as the electron beam scans over the 
specimen, the location of the characteristic x-rays emitted may be mapped in relation to 
the secondary electron image as seen in Figure 9.  
There are several variables that affect the emitted x-ray signal. These variables 
include the energy of the electron beam exciting the specimen (expressed as kilovolts), 
the distance of the specimen from the pole piece of the magnetic lens (working distance, 
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WD), the spot size of the focused electron beam (diameter in nm), and magnification (15, 
17). 
 
Figure 7: Spectrum showing x-ray photon emission from elements at energy levels 
between 0.0 kV and 3.0 kV on the x-axis, and 0 to 10,000 counts of x-ray on the y-axis. 
The area beneath each peak is used to determine the elemental weight percent.  
  
 
Figure 8: Report generated by Noran System Seven EDS software. 
 
The software used in this study to interpret the x-ray emission is Noran System 
Seven (NSS), which allows elements to be selected for quantitative analysis. The relative 
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weights of elements present in the specimen are expressed as weight percent (% Wt). 
This value represents the weight of elements present in the tissue excited by the electron 
beam. In this study, the main elements present in samples were rubidium, sodium, 
potassium, calcium, chlorine, carbon, nitrogen, oxygen, and silicon. As previously 
discussed, rubidium is a potassium congener and was used in this study to determine 
sodium potassium pump activity. Sodium, potassium, calcium and chlorine were present 
extracellularly as part of residual Krebs buffer remaining with the incubated cells. These 
elements also appear intracellularly based on their biological functions within viable 
cardiomyocytes (26).  Carbon, nitrogen and oxygen make up the majority cellular 
molecules (2). Finally, silicon is the primary component of the coverslips on which the 
samples were prepared and analyzed by SEM and EDS (9).  
 
Figure 9: Map of elemental density in a sample. The spatial density of the dots indicates 
the number of x-ray photons emitted for each of the elements. Elements are indicated on 
the top left-hand corner of each panel and a gray scale SEM image is displayed in the top 
left corner panel.  
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In viable cells, elements such as calcium, potassium, and sodium make up an 
approximate 4% of the cell mass. Water makes up an approximate 70% of the cell mass, 
and macromolecules composed of carbon, oxygen, nitrogen, and hydrogen make up 
approximately 30% (2). It is important to note that cells analyzed on the SEM are 
dehydrated as part of their preparation, which means that the values expressed in this 
study represent percentage of specimen dry weight. Furthermore, because of instrument 
limitations, quantitative information for hydrogen cannot be obtained EDS. Thus, with 
practically no water remaining in freeze-dried dehydrated cells, elemental composition is 
distorted. Carbon and nitrogen make up anywhere between 60-70%, and the remaining 
elements make up the rest.  
 
Data gathered are illustrated in a variety of useful modes. One such mode is a 
spectrum graph of the analysis as seen in Figure 7. The spectrum shows the x-ray energy 
levels (KeV) on the X-axis and x-ray photon counts at each energy level on the Y-axis. 
Each element emits x-ray photons at specific KeV energy levels depending on the 
electron orbitals (K, L, M) of the element. The amount of each element present in the 
sample can then be derived from the areas under the curve of the characteristic peaks and 
is expressed as weight percent. NSS also allows for manually focusing on a region of 
interest on the SEM specimen. Quantitative data gathered by the EDS at the specified 
area of interest is reported as weight-% as shown in Figure 8. 
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Materials and Methods 
Experimental Design 
 To examine the inhibitory effects of linoleic acid on sodium pumps, viable 
cardiomyocytes were isolated from rat hearts and incubated in various buffers. Since 
rubidium was a close congener of potassium, it was used as index for potassium uptake 
by isolated rat cardiomyocytes. Rubidium was measured by using EDS technology as 
weight percent within a cell. Rubidium weight percent of cells incubating in rubidium-
Krebs buffer was used as the experimental negative control expressing a baseline 
incorporation of rubidium in viable cardiomyocytes. Rubidium weight percent of cells 
incubating in Ouabain + rubidium-Krebs buffer was used as the experimental positive 
control expressing decreased incorporation of rubidium in viable cardiomyocytes due to 
Ouabain’s inhibitory effect on sodium pumps. Linoleic acid’s effect on sodium pumps 
was examined by incubating viable rat cardiomyocytes in L.A + Rubidium-Krebs buffer 
and then measuring rubidium weight percent of those cells by EDS.    
Rats 
 The use of rats for this study was approved by the Institutional Animal Care and 
Use Committee at Minnesota State University, Mankato (IACUC approval # 15-04).  
Thirty Wistar-Kyoto (WKY) rats were used for the trial sets of this project. To maintain 
consistency, only adult males were used for the experiments. The weight range for the 
rats was between 260 and 320 grams. The rats were housed in the Animal Care Facility in 
Minnesota State University, Mankato and were fed standard commercial chow and water 
ad lib. The rats were housed in 1600cm3 cages with wood chip bedding. Two rats were 
housed in each cage and the cages were in a room with a temperature set at 72° F and a 
12-hour light/dark cycle. 
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Rat Heart Isolation 
 The first step of the experimental procedures was to remove rat hearts for 
cardiomyocytes isolation. In preparation for removal, the rats were anesthetized using 3% 
Isoflurane in oxygen gas administered to the rats through a gas chamber. After 
approximately 5-7 minutes of the Isoflurane gas administration, the rats were completely 
anesthetized. The Isoflurane gas was then shifted from the gas chamber into an anesthesia 
mask, in which the muzzle of a rat was fully inserted. The rats were laid in a ventral view 
on a surgical pad.    
 The heart was then removed by opening the thoracic cavity through a transverse 
incision below the sternum and bilateral parasagittal cuts through the ventral thoracic 
wall. Once apparent, the attachment of the diaphragm was incised to expose the heart. 
The aorta was then identified and cut one centimeter away from heart. The heart was then 
excised from the pericardium and separated from the lungs. The isolated heart was placed 
in a beaker containing approximately 30ml of 0.9% saline cooled to 4o C to stop the 
heart-beat and allow for placement of a 16-gauge cannula in the aorta.  The tip of the 
cannula was advanced retrograde to the ostia of the coronary arteries and the cannula was 
secured in place with a ligature.  
 
Langendorff Apparatus and Administration of Digestive enzymes 
 The Langendorff system has a water-jacketed reservoir, infusion line, and organ 
chamber to maintain a constant temperature of infusate. The reservoir is located 
approximately 70 cm above the organ chamber to maintain a constant infusion pressure at 
around 52 mmHg. A sintered glass bubbler in the reservoir provides a means to deliver 
and saturate the infusate with oxygen gas. The Langendorff system allows for the 
perfusion of buffers containing tissue digestive enzymes. The digestive enzyme 
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collagenase type II (Worthington Biochemical Corp., Lakewood NJ) was used to break-
up collagen within cardiac tissue and separate cardiomyocytes. To prepare the 
collagenase solution, 60 ml of calcium-free Krebs solution was heated to 37⁰C, and 
0.060g of the collagenase was dissolved in the 37⁰C calcium-free Krebs solution. 
Once the heart was cannulated and connected to the Langendorff apparatus, an 
infusion of 50 ml of normal Krebs buffer solution warmed to 37⁰C was infused through 
the cannulated heart to initiate the heartbeat. During the infusion, the heart blanched from 
a red to a pale pink coloration and continued to beat.  After infusion with the initial buffer 
solution, 25 ml of the collagenase-Krebs buffer was delivered to the heart through the 
Langendorff system for approximately 10 minutes. Following the infusion of 
collagenase-Krebs solution, the heart was disconnected from the Langendorff apparatus 
and the cannula was removed. The heart tissue was then minced into approximate 3mm3 
pieces and incubated at 37oC in a petri dish filled with collagenase in calcium-free Krebs 
solution. The incubation period lasted 30 minutes on a dissection warming-plate set at 
37⁰C.  
Table 1: Krebs Buffer Solutions 
Buffer pH Composition 
Standard Krebs 7.35 
5 mM KCl, 2 mM CaCl2, 24 mM NaHCO3, 
1mM MgCl2, 115 mM NaCl, 10 mM HEPES, 
BSA and ddH2O 
Calcium-Free Krebs 7.35 Standard Krebs. Eliminated CaCl2, and adjusted pH to 7.35 
Rubidium-Krebs 7.35 Standard Krebs. KCl is substituted with RbCl and adjusted pH to 7.35 
Ouabain+ Rubidium-Krebs 7.35 Rubidium-Krebs + 10
-3M Ouabain, and 
adjusted pH to 7.35 
Linoleic Acid+ Rubidium-Krebs 7.35 
Two different concentrations of Linoleic Acid 
(10-3M and 10-6M) dissolved in Rubidium-
Krebs, and adjusted pH to 7.35 
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Cardiomyocytes Isolation (Figure 10) 
 After incubation in collagenase-Krebs buffer, the isolated cells in the buffer were 
pipetted into two 15-ml Falcon tubes, using disposable 3 ml pipettes. The two falcon 
tubes were centrifuged at 700 x g for 1 minute. The supernatant containing the 
collagenase solution was decanted. The remaining pellets containing the isolated 
cardiomyocytes were washed twice in calcium free Krebs to wash off residual 
collagenase and to ensure the termination of digestive enzyme activity. Each wash 
consisted of adding 2 ml of 37⁰C calcium-free Krebs solution to each of the two falcon 
tubes. The cell pellets were then resuspended into solution and centrifuged at 700 x g for 
1 minute. Following the two washes, 1 ml of 37⁰C rubidium-Krebs solution was added to 
each of the two pellets, and the cells were resuspended in the solution. Rubidium Krebs is 
a variant of the buffer where potassium is completely replaced with rubidium. The two 
falcon tubes were combined into a single tube resulting in a 2 ml cardiomyocyte cell 
suspension. The suspension was maintained at 37⁰C at all times on a heating platform. 
All buffer solutions used in this experiment were preheated to 37⁰C using a heating 
platform, and oxygenated using the scintered glass oxygen gas bubbler.   
 
Figure 10: Cardiomyocyte isolation procedure. 
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Trypan Blue 
 A Trypan Blue assay was conducted to confirm the viability of the isolated cells. 
This assay was used when there was a procedural change and when new batches of buffer 
or collagenase stock were being used to confirm proper cardiomyocyte isolation. To 
prepare the Trypan solution, 0.4 g of lyophilized Trypan were dissolved in 100 ml 
phosphate buffered saline (PBS) solution by slow-boil. The solution was let to cool to 
room temperature, and then stored in a 10⁰C refrigerator. To conduct the assay, 5µl of the 
Trypan solution were gently mixed with 45µl of the cardiomyocyte cell-suspension.  
Incubation was continued at 37oC on the remaining cell suspension. The Trypan blue/cell 
suspension assay mixture was incubated for 5 minutes at 37⁰C.  
 After the incubation period, the assay mixture was gently remixed using a 
micropipette, and then 20 µl were pipetted and dispensed on a slide. A coverslip was then 
gently applied onto the sample. The slide was observed on a Zeiss light-compound 
microscope at a total magnification of 400x. The trypan blue dye works as an exclusion 
assay, since viable cells with intact cellular membrane exclude the dye and remain 
unstained. Conversely, dead cells incorporate the dye and appear distinctly stained blue 
when viewed under a light compound microscope. The slide was observed in its entirety, 
and ratio of live-to-dead cells was determined. 
Contractility Studies  
 Contractility studies were done in order to examine the ability of isolated 
cardiomyocytes to function properly. The studies were an attempt to induce contractions 
of isolated cardiomyocytes to further confirm their viability. A 0.5ml sample of the 
cardiomyocyte cell-suspension was placed in a contractility apparatus (Figure 11). The 
apparatus consisted of a cell culture well with both a positive electrode and a negative 
electrode properly secured at opposite ends of the well. The electrodes were connected to 
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a power source supplying pulsed voltage with the parameters detailed in Table 2. The 
contractility apparatus including the 0.5ml of cardiomyocytes isolate was placed on an 
inverted microscope and was viewed at total magnification of 400x. Since 
cardiomyocytes function best around 37⁰C, the temperature of the well placed on the 
microscope was recorded for duration of 15 mins in 5 mins increments as seen in Table 3. 
To overcome the drop in temperature inside the contractility well, the well was placed 
inside a petri dish filled with 40⁰C distilled water. The power supply conditions were also 
manipulated in an attempt to induce contractions. 
 
Figure 11: Diagram illustrating contractility studies. 
 
  
Table 2: Power supply 
   
 
Frequency 5 pulses per second 
Delay 2 millisecond 
Duration 2 millisecond 
Voltage 0.1 Volts 
 
Table 3: Temperature of 
    Time (mins) Temperature (⁰C) 
0 37 
5 26 
10 23 
15 23 
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Cell Adhesion onto Coverslips 
 An investigative step was conducted to estimate the time needed for a cell to 
precipitate out of the saline preparation, and settle onto the coverslip. Samples of isolated 
cardiomyocytes in 1 ml of 0.9% saline were observed under a light compound 
microscope. The microscope was first adjusted in fine focus onto a slide at total 
magnification of 400x. Then a drop of the cell isolate was placed onto the slide in focus. 
Time was determined from placement of drop until cells settled on the surface of slide in 
focal plane. The time for the cells to settle was approximately 20-30 sec.  Subsequently, 
1.5 min after placement of the suspension on the coverslip, the solution was perturbed 
using a P-20 pipette to determine whether the cardiomyocytes had settled completely 
onto the coverslip.  
 
SEM/EDS Sample Preparations 
 After incubation in treatment buffers, cardiomyocyte samples were washed twice 
in 0.9% saline solution. The wash consisted of centrifugation of cells incubated in 
treatment buffers at 700 x g for 1 minute, the supernatant was then decanted. The pellet 
of cells was resuspended in 1 ml of 0.9% saline solution, and centrifuged at 700 x g for 1 
minute, and the process was repeated for the second wash. Following the two washes, the 
cells were suspended in 0.25 ml of 0.9% saline solution. To freeze-dry the samples, 0.25 
ml of each cell preparation were dispensed evenly on two coverslips for a given 
treatment. The coverslips were submerged for10 seconds in liquid nitrogen, and 
immediately placed on the cold plate of a VirTis 4KB Benchtop freeze drying apparatus 
pre-set at -60⁰ C. The samples were freeze-dried at 095mTorr for 12 hours.  
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SEM/EDS Procedure 
 The scanning electron microscope JEOL JSM 6510LV (JEOL U.S.A, Inc.) 
equipped with a Thermo NORAN silicon drift ultra-dry detector, EDS system, and NSS 
system-7 analysis software (Thermo Scientific) was used to analyze the elemental content 
of the samples.  The samples were not sputter coated with conductive material (i.e. gold) 
minimize potential interference in EDS analysis.   
 
 
Figure 13: An SEM of an isolated cardiomyocyte not accepted for EDS analysis. This cell was 
rejected from analysis because it was heavily covered in salts. Sharp-edged salts could be seen 
inside the region highlighted by the dashed green box x2,300. 
 
For EDS analysis, samples were analyzed at 8000X so that the cell encompassed the 
entirety of the field of view. Samples were analyzed with an accelerating voltage of 20 
kV, with a spot size of 50 nm. These parameters were decided based on preliminary trials 
for optimal detection of rubidium at different spot sizes and kV levels (Appendix B and 
Appendix C). A cell was selected for EDS analysis if it was fully-intact and flattened, not 
folded, on the surface of the coverslip. Furthermore, each of the analyzed cells was free 
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of salts or other debris within the entirety of the cell’s surface. Cells with salt crystals 
embedded on the surface (Figure 12) were not selected for analysis due to inaccurate 
results caused by salt crystals and debris. Analysis was conducted to detect element 
weight % for sodium (Na+), carbon (C), nitrogen (N), oxygen (O), potassium (K), 
calcium (Ca), silicon (Si), and rubidium (Rb). These elements had characteristic x-ray 
photon energy peaks between 0 and 3.0 KeV, and a 5-minute scan yielded x-ray counts 
between 0 and 10,000 at characteristic energies. The main peaks were observed for 
sodium (Na+) at 1.04 KeV, for carbon (C) at 0.27 KeV, for nitrogen (N) at 0.39 KeV, for 
oxygen (O) at 0.52 KeV, for potassium (K) at 3.31 KeV, for calcium (Ca) at 0.34 KeV, 
for silicon (Si) at 1.73 KeV, and for rubidium (Rb) at 1.69 KeV. Reports generated for 
the samples included a quantitative report, mapping of elements, and spectrum readings.  
 
 
 
Figure 13: SEM of an isolated cardiomyocyte accepted for EDS analysis during the preliminary 
phase of the study. This cell is viewed at a magnification of x2,300, 15kV, and a spot size of 
33nm.  
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The above procedure was used in preliminary trials to determine optimal 
conditions for analysis and to examine linoleic acid’s effects on cardiomyocyte rubidium 
levels. The preliminary trials included optimal time for rubidium uptake, optimal electron 
beam spot size, optimal electron beam accelerating voltage, and confirmation of optimal 
Ouabain concentration to induce inhibition of rubidium uptake. The methodology and 
results of the preliminary trials are included in Appendices A-E. 
 
The Effects of Linoleic Acid on Cardiomyocyte Rubidium   
Based on the preliminary trials (Appendices A-E), the experimental procedure and 
analytical conditions were set to examine the proposed hypothesis in ten replicates. Each 
experimental replicate included cells incubating in Rb-Krebs buffer (negative control), 
10-3 M Ouabain + Rb-Krebs buffer (positive control), 10-3 M L.A+ Rb-Krebs buffer, and 
10-6 M L.A+ Rb-Krebs buffer. All cells for one experimental replicate were isolated from 
one rat heart (Figure 10) and divided equally between the four treatment buffers. Cells in 
each treatment incubated for two hours, which was determined to be optimal incubation 
period as seen in Appendix A. For each experimental treatment, 10 cells were randomly 
selected for analysis. Parameters for SEM/EDS analysis were decided based on the 
results of preliminary trials (Appendix B and C). As previously mentioned, cells in all ten 
experimental replicates were analyzed at a magnification of x8000, a spot size of 50 nm, 
and a voltage of 20 kV.   
 
Statistical Analysis    
 Microsoft Excel data for each experimental trial was transferred to Statistical 
Package for Social Sciences (SPSS) software. The data groups were analyzed for normal 
distribution using the Wilk-Shapiro test with p-value greater than 0.05 considered 
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normally distributed. Levene’s test for equality of variance was conducted under the 
assumption that variance of data in treatment groups were not equal. Variances were 
considered equal if p-values were greater than 0.05. Analysis of Variance (ANOVA) test 
was conducted for experimental groups to determine if there were statistically significant 
differences among the means of treatment groups. An ANOVA P-values less than 0.05 
indicated that there was a significant difference among treatment groups. If significant 
differences were found, then Tukey’s post-hoc test was conducted to determine where the 
significance lies among the groups. Differences identified by the Tukey post-hoc test 
were considered to be significant if p was less than 0.05.   
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Results 
Viability of Cells  
 Observed cardiomyocytes appeared to be rectangular in shape and had an 
approximate area between 900µm2 and 1650µm 2 as seen in Figure 13. Cardiomyocytes 
were examined for viability using a Trypan Blue exclusion test. This process was 
performed when there was a change in procedure or when a new batch of buffer and 
collagenase were used. As shown in Figure 14, some cells incorporated the dye, and thus 
were considered dead, while other cells did not incorporate the dye, and therefore were 
considered viable. Preparations of isolated cells producing a ratio as low as one-to-one 
live-to dead cells were considered an acceptable batch for subsequent incubation in 
treatment and analysis.  
Contractility studies were also conducted. However, cardiomyocyte contractions 
were not observed and the cardiomyocytes appeared to be in a hyper-contracted state as 
described by Dalen et al (6). The surface of the cells had a shriveled appearance that was 
highly wrinkled. Often small blebs protruded from the surface of the cells and were 
probably mitochondria squeezed towards the cell surface (6). Furthermore, the 
appearance of isolated cardiomyocytes in this study may have been distorted because of 
the freeze-drying procedure.   
 
Figure 14: Image showing A) a viable cardiomyocyte, and B) a dead cardiomyocyte 
Magnification x400. 
A 
B 
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The Effects of Linoleic Acid on Cardiomyocyte Rubidium 
 The main question of this thesis study was “how would linoleic acid effect 
rubidium uptake in isolated rat cardiomyocytes?” Table 4 shows the mean weight percent 
of rubidium for each of the four treatment groups in ten replicates. In each of the ten 
trials, the rubidium levels were measured in ten cardiomyocytes for each of the treatment 
groups. Raw data for each experimental replicate are listed in Appendix F.  The mean and 
standard errors for each treatment are expressed numerically at the bottom of Table 4 and 
graphically in Figure 15.  
 
Table 4: The Effects of Linoleic Acid and Ouabain on Cardiomyocyte Rubidium 
 
 Mean Rb Weight Percent per Replicate for different Treatments  
Replicate 
Rb Krebs 
Without 
Treatment 
10-6 M Linoleic 
Acid 
+Rb Krebs 
10-3 M Linoleic 
Acid 
+Rb Krebs 
Ouabain 
(10-3 M) 
+Rb Krebs 
1 1.089 ± 0.206 1.264 ± 0.303 1.445 ± 0.329 1.024 ± 0.132 
2 2.096 ± 0.177 0.461 ± 0.140  0.528 ± 0.191 0.729 ± 0.165 
3 1.474 ± 0.153 0.425 ± 0.199 1.166 ± 0.222 0.629 ± 0.113 
4 1.088 ± 0.239 0.521 ± 0.233 0.683 ± 0.254 0.569 ± 0.195 
5 0.863 ± 0.270 1.536 ± 0.211 -- 0.679 ± 0.214 
6 1.152 ± 0.153 1.097 ± 0.338 0.710 ± 0.230 0.29 ± 0.140 
7 1.312 ± 0.145 0.886 ± 0.128 0.92 ± 0.337 0.586 ± 0.232 
8 1.082 ± 0.174 0.444 ± 0.210 0.92 ± 0.224 0.732 ± 0.223 
9 1.236 ± 0.193 0.675 ± 0.184 0.701 ± 0.171 1.123 ± 0.218 
10 1.399 ± 0.219 0.749 ± 0.189 1.059 ± 0.203 0.654 ± 0.213 
Average 1.279 ± 0.075 0.805 ± 0.121 0.903 ± 0.095 0.701 ± 0.073 
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For average rubidium weight percent per replicate, cells incubated in “Rb-Krebs 
without treatment” resulted in a mean of 1.279 +/- 0.075, and a Wilk-Shapiro normal 
distribution p-value of 0.061. Cells incubated in 10-3 M L.A. resulted in a mean rubidium 
weight percent of 0.903 +/- 0.095, and Wilk-Shapiro normal distribution p-value of 
0.652. It is important to note that the L.A. concentration of 10-3 M had only nine 
replicates, whilst all other treatments had ten. The missing replicate was a trial that failed 
to produce ten acceptable cells; thus the trial was considered inadequate for analysis. 
Cells incubated in 10-6 M L.A resulted in a mean rubidium weight percent of 0.805 +/- 
0.121, and Wilk-Shapiro normal distribution p-value of 0.193. Cells incubated in 
“Ouabain + Rb-Krebs” resulted in a rubidium weight percent mean of 0.701 +/- 0.073, 
and Wilk-Shapiro normal distribution p-value of 0.349. All treatment groups were 
considered to have a normal distribution of values. Levene’s test for equality of variance 
yielded a p-value of 0.382, which indicates that variances within treatment groups are 
equal amongst all groups. A one-way ANOVA resulted in a p-value of 0.002, indicating a 
significant difference among groups. The Tukey post-hoc multiple comparison test 
indicated that cells incubated in both treatment groups “Ouabain + Rb-Krebs” (p-
value=0.001), and “10-6 M L.A” (p-value=0.010) had statistically significant lower 
average rubidium weight percent values compared to cells incubated in “Rb-Krebs”. 
There was no statically significant difference between the treatment groups “10-3 M L.A” 
(p-value=0.64) and “Rb-Krebs”. Also, there were no statistically significant difference 
amongst the treatment groups “10-3 M L.A”, “10-6 M L.A”, and “Ouabain + Rb-Krebs” 
(All p-values > 0.05).    
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Figure 15: Mean cardiomyocyte rubidium weight percent. Error bars represent Standard 
Error. Stars indicate significant difference from “Rb Krebs without Treatment” (P<0.05).  
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Discussion 
             This study was designed to examine the potential of linoleic acid as an inhibitor 
of sodium potassium pump activity. This was done by measuring rat cardiomyocyte 
rubidium levels using EDS. It was found that the linoleic acid concentration 10-6 M, and 
not 10-3 M, exhibited an inhibitory effect on rubidium uptake. Several studies have shown 
that linoleic acid metabolites are incorporated into the phospholipids of cellular 
membrane in a manner that can alter the functions of cellular membranes (12, 32). Ha et 
al. proposed that linoleic acid molecules interject within the cellular membrane in regions 
close to sodium potassium pumps, and that disrupts the cellular membrane fluidity and 
the sodium pump function in the process (12). One potential explanation for the lack of 
inhibitory effect by the higher concentration of linoleic acid, 10-3 M, is increased non-
specific lipid interactions caused by the hydrophobic nature of linoleic acid, which may 
alter and counter the inhibitory effect otherwise observed with the lower linoleic acid 
concentration at 10-6 M. Secondly, downregulation or upregulation of transmembrane 
enzymes involved in ion movement across cellular membranes could be another potential 
explanation.  Linoleic acid was shown to downregulate the expression of specific 
enzymes, such as desaturase, at a transcriptional level by acting on sterol regulatory 
element binding protein (SREBPs) (32). Thirdly, linoleic acid was shown to have several 
physiological effects both through one of its isomers or as a precursor of a biologically 
active compound (30). For example, linoleic is a precursor of prostaglandins through the 
intermediate arachidonic acid (30). Prostaglandins are a biologically active lipid 
compounds with hormone-like effects, and so perhaps at increased concentrations, 
linoleic acid may affect cellular element concentration differently-than at lower 
concentrations- though hormone like interactions. Finally, the lack of observed inhibition 
by 10-3 M linoleic acid concentration could be due to a statistical artifact. Statistically, the 
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treatment 10-3 M had a smaller sample size, compared to the other treatment groups, as 
no sufficient data was obtained from the 10-3 M within trial set 5 (Appendix F).  
 
Cardiomyocyte viability 
The viability of isolated cardiomyocytes was confirmed by the trypan blue assays 
whenever a new stock of buffers was used or to confirm a change in cardiomyocyte 
isolation methodology. It is important to note that with the trypan blue assays, a ratio as 
low as one-to-one live-to-dead cells was accepted. This, of course, introduces the chance 
that some of the cells analyzed might have been dead cells. In addition, no confirmation 
of cell viability was conducted following the 2-hour incubations, which could also mean 
that decreased cardiomyocyte rubidium levels observed in cells treated with Ouabain and 
linoleic acid were a result of cell death caused by Ouabain or linoleic acid. To better 
understand the results produced in this thesis, it would be important to examine the effect 
of cellular death on rubidium incorporation. It would also be worthy of considerations to 
confirm the viability of cells post-incubation in the various treatment buffers.  
To further confirm the viability of isolated cardiomyocytes, examination of 
cardiomyocyte contractility was conducted. The aim was to demonstrate that these 
isolated cardiomyocytes were not only viable, but they were also functioning. However, 
the contractility of the cardiomyocytes could not be demonstrated in this thesis. The most 
likely explanation for lack of contractility is that the cells appeared to be hypercontracted 
state with similar morphology to what Dalen et al. described (6). In fact, adult 
cardiomyocytes, such as the ones isolated in this study, are difficult to induce in-vitro 
contractility and that neonatal cells are preferred amongst researchers due to their ability 
to contract in-vitro (3).   
 
40 
 
Cellular Rubidium Levels 
              The cellular levels of rubidium were most likely a result of the sodium 
potassium pump transport. There is a chance, however, that rubidium was incorporated 
into cardiomyocytes through other cellular membrane channels or pumps.   Previous 
work has indicated that rubidium is actively transported into cells through sodium 
potassium pumps (4,18, 21). In this thesis, Ouabain, a known inhibitor of the sodium 
potassium pump, reduced cardiomyocyte rubidium levels, providing evidence for cellular 
uptake of rubidium through sodium potassium pumps.  The rubidium levels inside the 
cell boundaries were less than the levels outside the cell boundaries as seen in Figure 16, 
qualitatively, and Figure 17, quantitatively. This indicates that perhaps the cellular 
membranes were functioning as a selective barrier against rubidium. The external 
environment of the cells was composed of residual Rb-Krebs salts and saline. Finally, to 
examine whether rubidium detected was on the surface of cells or inside the cells, a 
preliminary study was conducted using different accelerating voltages of the electron 
beam. With voltage increases, the electron beam penetrates deeper into the sample 
(appendix C). There was a drop in rubidium levels detected at voltage levels of 25 and 30 
kV where the electron completely penetrated through the sample. At 15 kV, the electron 
beam penetration was not as deep and the EDS detected moderate levels of rubidium. 
And at 20 kV, the electron beam went deeper into cells and detected significantly higher 
levels of rubidium as seen in Appendix C. This indicates that at the 20 kV level, the 
electron beam wasn’t deep enough to over-shoot cells and not shallow to pick surface 
rubidium. Instead, at 20 kV the EDS detected rubidium incorporated inside isolated cells.   
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Figure 16: Scanning electron micrograph of cardiomyocyte and its immediate 
surroundings (left) with corresponding map of rubidium (right). x1,600. 
 
 
Figure 17: Elemental composition of the areas scanned in Figure 16. Left panel lists 
weight percent of elements outside the cell boundary. Right panel lists weight percent of 
elements inside the cell boundary. x8,000. 
  
 
 There was a significant concern regarding the close proximity of silicon and 
rubidium peaks on the EDS spectrum as seen in Figure 7. Silicon, the main component of 
the coverslips on which cells were prepared, has a peak at 1.73 kV on the spectrum 
whereas rubidium has a peak at 1.69 kV on the spectrum. The proximity of the peaks 
raised a concern that the silicon from the coverslip interfered with rubidium 
measurement. To understand the degree of interference by silicon, the rubidium levels 
from cells prepared on a graphite, or carbon, support were compared to those mounted on 
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a silicon coverslip (Appendix E).  The results indicated that primary element detected was 
rubidium and not silicon. However, use of carbon support in the main experiment made it 
impossible to detect cellular carbon, which was an indicator for accepting cells for 
SEM/EDS analysis. As previously mentioned the element carbon makes up a large 
portion of dried cells, and carbon stubs as a background to isolated cells distorts carbon 
element weight percentages detected by EDS. It is also important to note that throughout 
the entire study, the percentage of silicon remained consistent and did not vary with 
treatment. This was especially the case when cells were analyzed at 20 kV. Silicon-based 
coverslips were chosen as the surface to prepare samples only because of their consistent 
success in allowing intact cells to adhere to their surface throughout preparation process. 
Cells must also be able to settle out of solution and adhere on the surface of preparation 
before deep freezing in liquid nitrogen. Other surfaces such as aluminum and carbon 
specimen mounts and carbon tape did not provide an adequate surface for cell adhesion 
or for analysis  
             In the preliminary phase of this study, two biological phenomena were replicated. 
The heart cells in this study incorporated rubidium in a time dependent fashion similar to 
that reported by Kupriyanov et al (21).  Cardiomyocyte rubidium in isolated cells over 
time was observed similarly in this study as seen in Appendix A.   Furthermore, this study 
showed that treatment with Ouabain, a known inhibitor of the sodium potassium pump, 
reduced myocardial rubidium levels indicating that the observed cellular rubidium levels 
in this study were a result of the sodium potassium pump. 
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Limitations 
 It is important to note that there were several limitations to this study. Firstly, 
EDS technology is considered a semi-quantitative type of measurement since it only 
presents a percentage of the elements present in the cell and not the actual molecular 
composition of the cell (13).  For instance, water comprising over 70% of the cell was 
removed by the dehydration process to prepare specimens. Secondly, the actual and 
physical depth of an isolated cardiomyocyte could not be measured nor could the depth of 
electron beam penetration of electron beam into the cell. However, the presence of silicon 
from the coverslip suggested that the beam penetrated through the cell exciting the 
elements within. Finally, the state of contracting versus relaxed cells was not known in 
the SEM/EDS analysis. However, from the observations of Dalen (6), the cardiomyocytes 
in the present study appeared to be in a hypercontracted state. This could have possibly 
effected the folding of a cell onto itself in a contracted state, which could alter elemental 
composition per unit area. 
 
Future studies  
Several experiments using the same experimental design of this study could be 
conducted to further understand the mechanism of inhibition exhibited by linoleic acid. 
One proposed experiment is to treat isolated cardiomyocytes with “Rb-Krebs + linoleic 
acid + Ouabain”, “Rb-Krebs + linoleic acid”, and “Rb-Krebs + Ouabain”. This 
experiment would show whether linoleic acid has an added effect of inhibition on top of 
the established effects of Ouabain. Rubidium weight percent within elements would be 
the experimental index for sodium pump inhibition as previously established. If the 
treatment group “Rb-Krebs + linoleic acid + Ouabain” was found to have decreased 
levels of rubidium compared to “Rb-Krebs + Ouabain”, then this indicates that inhibition 
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is perhaps observed through several pathways. The pathway of inhibition is of great 
significance to this study, since Ouabain’s and digoxins competitive inhibition of 
potassium incorporation at the E2P conformation of sodium pumps results in the digitalis 
toxicity symptoms CHF patients’ experience. A non-competitive inhibition through an 
allosteric site or an inhibition of sodium potassium pumps through disruption of cellular 
membrane offers an entirely new realm of possibilities for therapeutic specificity and 
regulation.  
Also, the differential effect of linoleic acid concentration makes it crucial to 
examine other concentrations of linoleic acid. It is suggested for future studies that a dose 
dependent response is conducted using the same experimental design. This will further 
our understanding of linoleic acids effects on sodium potassium pumps, and will lead to 
the development of more solid ground for therapeutics. Furthermore, other fatty acids 
such as oleic acid and metabolites of linoleic acid should also be examined using this 
same experimental design. Other studies have shown that those metabolites of linoleic 
acid and other fatty acid exhibit biologically relevant effects on isolated cells (25, 32). 
 Several suggestions for future study were developed based on findings and course 
of research. It is suggested to utilize a single cardiomyocyte cell line from which 
treatments of linoleic acid and controls are applied. This will decrease the experimental 
steps preceding incubation in treatments, which in turn will reduce confounding variable 
including intrinsic differences in rats being used, and experimental and equipment errors 
in cardiomyocyte isolation steps. Such errors could significantly vary viability 
percentages of isolated cells, and it could also vary the fitness level of cells to exchange 
sodium and rubidium ions. This proposed cell line, however, could possibly introduce a 
new set of variable such as maintenance of cell line and potential bacterial infections.  
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 To further confirm findings from this study, it is highly suggested that a detailed 
examination is conducted of potassium, sodium and calcium element weight percentages 
included in EDS (NSS) data sets obtained throughout the study. The aforementioned 
elements have biologically significant and independent correlations with rubidium uptake 
levels by isolated cardiomyocytes. Since the isolated cells were incubated in a potassium-
free Krebs buffer, it is proposed that cells incorporating minimal levels of rubidium 
would contain higher levels of potassium. Potassium naturally leaks from inside the cell 
onto the extracellular matrix in efforts to maintain a balanced ionic gradient about the 
cellular membrane. If the sodium pump activity of cells incubating in rubidium is 
inhibited, 1) the cell wouldn’t incorporate rubidium, and 2) leakage of intracellular 
potassium isn’t favorable unless the cell is in a hypotonic state, and therefore potassium 
is retained inside the cell. 
 Sodium is the element directly exchanged for rubidium through sodium-
potassium pump activity. It is hypothesized that as rubidium levels inside the cells 
decrease, through inhibition of sodium potassium pumps, an increase of intracellular 
sodium levels will be observed. With the concurrent experimental design, cells that 
completed incubation in treatment groups were washed in 0.9% saline, freeze-dried, and 
then analyzed on the SEM/EDS. This step causes an abundance of sodium molecules 
being detected by EDS throughout the sample preparation, since the cells are suspended 
in a sodium salt buffer. To analyze intracellular sodium levels, it is also suggested that 
the 0.9% saline solution is replaced with another solution such as concentrated glucose. A 
highly concentrated glucose solution would create a hypotonic environment for the cells, 
which would force the cells to retain their intracellular content in a fashion similar to the 
saline solution. This will result in more accurate EDS sodium readings since excess 
extracellular sodium will not interfere with the analysis. An observation of increasing 
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sodium levels as rubidium decreases inside cells is further confirmation of the inhibitory 
effects of linoleic acid.  
 Finally, calcium levels are a great indicator that indeed an inhibition of sodium 
pumps is occurring. It is hypothesized that in cardiomyocytes with decreased rubidium 
element weight percentages there will be a significant increase in intracellular levels. 
This is due to the aforementioned coupling of sodium potassium pumps and NCX 
activities. Increased intracellular levels of calcium is a promotor of more forceful cardiac 
contractions. The significance of such finding would further indicate the validity of 
utilizing linoleic acid as a treatment for congestive heart failure.  
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Appendices  
 
 Before examining linoleic acid’s effects, several preliminary experiments were 
done to either to determine optimal parameters and conditions for SEM/EDS analysis. 
The cardiomyocyte rubidium levels in isolated cells were analyzed to validate the 
experimental design. Determination of most effective KeV level and spot size was done 
to set optimal parameters for analysis. Confirmation of the suggested Ouabain 
concentration’s effect was also conducted to illustrate inhibition of rubidium uptake. All 
data for preliminary studies is described and analyzed below in the following appendices. 
Also included at the end of this section is the raw data for the main trial set examining 
linoleic acid’s effects on cardiomyocyte rubidium weight percent. 
 
Appendix A:  Changes in Cellular Rubidium Levels over Time 
 Cells were prepared as seen in Figure 10. Five 15 mL tubes were labeled with the 
time points, and the stock of isolated cardiomyocytes was divided upon the five tubes. 
Samples were left to incubate and were freeze-dried when they reached the end of their 
time point. Samples of the time point “0.0 hours” did not incubate, and time point “2.0 
hours” samples incubated for two hours, and so on. Ten cells were analyzed by 
SEM/EDS for each time point with the SEM electron beam set at 15 kV and a spot size of 
40 nm. Rubidium weight-percent for all cells in each time point is included in Table 5. 
Averages and standard error were calculated and graphed as illustrated in Figure 19.  
 For average cardiomyocyte rubidium weight percent, time point “0.0 Hours” 
resulted in mean of 0.033 +/- 0.028, and a Wilk-Shapiro normal distribution p-value of 
0.000. Time point “0.5 Hours” resulted in mean of 0.117 +/- 0.058, and a Wilk-Shapiro 
normal distribution p-value of 0.001. Time point “1.0 Hours” resulted in mean of 0.126 
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+/- 0.054, and a Wilk-Shapiro normal distribution p-value of 0.006. Time point “1.0 
Hours” resulted in mean of 0.126 +/- 0.054, and a Wilk-Shapiro normal distribution p-
value of 0.006. Time point “1.5 Hours” resulted in mean of 0.249 +/- 0.056, and a Wilk-
Shapiro normal distribution p-value of 0.605. Time point “2.0 Hours” resulted in mean of 
0.473 +/- 0.144, and a Wilk-Shapiro normal distribution p-value of 0.126. Only time 
points “1.5 Hours” and “2.0 Hours” were considered normally distributed, and time 
points “0.0 Hours”, “0.5 Hours”, “1.0 Hours” were considered not normally distributed. 
Levene’s homogeneity test of variance resulted in a p-value > 0.000, which indicates that 
the variance within time point cells’ rubidium percentages are not equal amongst the 
different time points. The ANOVA test resulted in a p-value of 0.003 indicating 
significant differences amongst the time point groups, which was further confirmed by 
the more statistically robust Welch-ANOVA’s p-value of 0.008. Significant difference 
between the treatment groups were identified using the Tukey post-hoc test. It indicated 
that time point “2.0 Hours” was significantly higher in cardiomyocyte rubidium weight 
percent than time points “0.0 Hours” (p=0.002), “0.5 Hours” (p=0.021), and “1.0 Hours” 
(p=0.025), but not time point “1.5 Hours” (p=0.278).   
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Table 5: Rubidium Weight Percent Values at Different Times  
Cell # 0.0Hr 0.5Hr 1.0Hr 1.5Hr 2.0HR 
1 0 0.33 0.22 0 1.05 
2 0 0.29 0.23 0.33 1.16 
3 0 0.01 0 0.4 0 
4 0 0.05 0.31 0.53 0.96 
5 0 0 0 0 0.13 
6 0 0.49 0 0.2 0 
7 0 0 0.02 0.13 0.48 
8 0.05 0 0.48 0.38 0.33 
9 0 0 0 0.35 0 
10 0.28 0 0 0.17 0.62 
Average 0.033 0.117 0.126 0.249 0.473 
Standard 
Error  0.028 0.058 0.054 0.056 0.144 
 
 
 
Figure 19: Cardiomyocyte rubidium levels at time intervals. Values are mean and 
standard error. Star indicates significant difference (p < 0.05) from the treatment groups 
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Appendix B  Optimum Electron Beam Spot Size 
 Cells were prepared as seen in Figure 10. The sample of isolated cardiomyocytes 
incubated for two hours in rubidium-Krebs, and then freeze-dried and prepared for 
SEM/EDS analysis. Six cells were picked for SEM/EDS analysis, and each cell was 
analyzed at spot size 20 nm, 30 nm, 40 nm, 50 nm, and 60 nm. The kV of the electron 
beam was set to 15 kV during the analysis of all different spot size treatment groups. 
Rubidium weight percent for all cells in each spot size group is included in Table 6. 
Averages and standard error were calculated and graphed as illustrated in Figure 20. 
 For average cardiomyocyte rubidium weight percent, the spot size 20 nm resulted 
in a mean 0.150 +/- 0.086, and a Wilk-Shapiro normal distribution p-value of 0.056. The 
spot size 30 nm resulted in a mean 0.095 +/- 0.034, and a Wilk-Shapiro normal 
distribution p-value of 0.593. The spot size 40 nm resulted in a mean 0.113 +/- 0.060, and 
a Wilk-Shapiro normal distribution p-value of 0.015. The spot size 50 nm resulted in a 
mean 0.366 +/- 0.117, and a Wilk-Shapiro normal distribution p-value of 0.858. The spot 
size 60 nm resulted in a mean 0.483 +/- 0.127, and a Wilk-Shapiro normal distribution p-
value of 0.561. All spot size groups were considered normally distributed except the 
group 40 nm. Although the treatment group 60 nm for a spot size yielded the best 
rubidium weight percent in the analysis, it produced a distorted imaging and therefore, 50 
nm was used as the standard spot size in subsequent experimental trials. 
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Table 6: Rubidium weight percent values with different electron beam spot sizes at 15 
kV accelerating voltage 
 
Cell # 20nm 30nm 40nm 50nm 60nm 
1 0.53 0.09 0.3 0.83 0.44 
2 0 0.04 0 0 0 
3 0 0.05 0 0.14 0.4 
4 0.12 0 0.08 0.35 0.77 
5 0 0.22 0.3 0.41 0.88 
6 0.25 0.17 0 0.47 0.41 
Average 0.150 0.095 0.113 0.366 0.483 
Standard 
Error 0.086 0.034 0.060 0.117 0.127 
 
 
 
 
Figure 20: Cardiomyocyte rubidium levels at different SEM spot size. Values are mean 
and standard error. Star indicates significant difference (p < 0.05) from other treatment 
groups. 
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Appendix C  Optimum Voltage of Electron Beam 
 
Cells were prepared as seen in Figure 10. The sample of isolated cardiomyocytes 
incubated for two hours in rubidium-Krebs, and then freeze-dried and prepared for 
SEM/EDS analysis. Six cells were picked for SEM/EDS analysis, and each cell was 
analyzed at KeV level of 15kV. 20kV, 25kV, and 30kV. The SEM spot size was set to 40 
nm during the analysis. Rubidium weight percent for all cells in each KeV level group is 
included in Table 7. Averages and standard error were calculated and graphed as 
illustrated in Figure 21. 
For average cardiomyocyte rubidium weight percent, the KeV level 15kV resulted 
in a mean 0.433 +/- 0.135, and a Wilk-Shapiro normal distribution p-value of 0.911. The 
KeV level 20kV resulted in a mean 1.026 +/- 0.0.260, and a Wilk-Shapiro normal 
distribution p-value of 0.017. The KeV level 25kV resulted in a mean 0.016 +/- 0.017, 
and a Wilk-Shapiro normal distribution p-value < 0.000. The KeV level 30kV resulted in 
a mean 0.021 +/- 0.007, and a Wilk-Shapiro normal distribution p-value of 0.007. All 
KeV groups were considered to have normal distribution except 25kV. Levene’s test for 
homogeneity of variance resulted in a p-value of 0.000, which indicated that the variance 
within KeV groups were not equal amongst all KeV groups. The ANOVA test resulted in 
a p-value of 0.000 indicating significant differences amongst the KeV groups. Using the 
Tukey post-hoc test, the 20kV group was found to detect significantly higher rubidium 
weight percent than 15kV (p=0.044), 25kV (p=0.001), and 30kV (p=0.001).  
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Table 7: Rubidium Weight Percent Values with Different Electron Beam Accelerating 
Voltages. 
Cell # 15kV 20kV 25kV 30kV 
1 0 0.41 0 0.02 
2 0.26 0.72 0.1 0.04 
3 0.25 0.44 0 0.03 
4 0.92 1.34 0 0 
5 0.5 1.18 0 0 
6 0.67 2.07 0 0.04 
Average 0.433 1.026 0.016 0.021 
Standard 
Error 0.135 0.260 0.017 0.007 
 
 
 
Figure 21: Cardiomyocyte rubidium levels at different SEM accelerating voltages. 
Values are mean and standard error. Star indicates significant difference (p < 0.05) from 
other treatment groups. 
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Appendix D  Ouabain Inhibition of Cardiomyocyte Rubidium Incorporation 
 
Ouabain served as a positive control for inhibition of the sodium potassium 
pump’s incorporation of rubidium. It was suggested from the literature that 10-3 M of 
Ouabain in Krebs-buffer is ideal to induce such inhibition (35). To confirm Ouabain’s 
effect on cardiomyocyte rubidium weight percent, cells were prepared as seen in Figure 
10. The sample of isolated cardiomyocytes was then split in equal volume and each 
fraction was incubated for two hours in either “rubidium-Krebs” or in “10-3 M Ouabain + 
rubidium-Krebs”. Samples were then freeze-dried and prepared for SEM/EDS analysis. 
10 cells were SEM/EDS analyzed from each treatment. Rubidium weight percent for all 
cells in each treatment is included in Table 8. Averages and standard error were 
calculated and graphed as illustrated in Figure 22.  
For average cardiomyocyte rubidium weight percent, cells incubated in 
“rubidium-Krebs” yielded a mean of 1.981 +/- 0.164, and a Wilk-Shapiro normal 
distribution p-value of 0.987. Cells incubated in “10-3 M Ouabain + rubidium-Krebs” 
yielded a mean of 0.294 +/- 0.120, and a Wilk-Shapiro normal distribution p-value of 
0.010. The “10-3 M Ouabain + rubidium-Krebs” was considered to have a non-normal 
distribution of values. To compare the means of the two treatment groups, an independent 
sample t-test was performed. Levene’s test for equality of variance resulted in a p-value 
of 0.432, which indicates that variances within cells treated in “rubidium-Krebs” and 
cells treated in “10-3 M Ouabain + rubidium-Krebs” are equal between the two treatment 
groups. Under the assumption of equal variances, the independent sample t-test resulted 
in a two-tailed p-value of 0.000. This confirms that the intracellular rubidium percentages 
within cells treated in “rubidium-Krebs” are significantly higher the than intracellular 
rubidium percentages within cell treated in “10-3 M Ouabain + rubidium-Krebs”. 
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Table 8: Rubidium Weight percent values of cells treated incubated with Ouabain 
 
Cell # Rb Krebs 10-3 M Ouabain + Rb Krebs 
1 1.92 0 
2 1.63 0.83 
3 1.75 0.62 
4 2.18 0.97 
5 2.57 0.13 
6 2.4 0.36 
7 1.93 0.03 
8 1.53 0 
9 1.09 0 
10 2.81 0 
Average 1.981 0.294 
Standard 
Error 0.164 0.120 
 
 
 
 
 
 
Figure 22: Effect of Ouabain (10-3M) on cardiomyocyte rubidium weight percent. Values 
are mean and standard error. Star indicates significant difference (p < 0.05) from other 
treatment group. 
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Appendix E 
Finally, to conclude the preliminary studies, the nature of rubidium signals 
detected by EDS needed to be examined. Incubated samples were prepared on coverslips 
obtained from Fisher Scientific, and those coverslips are composed of Borosilicate (8). 
Borosilicate makes a type of glass composed of a mixture of the elements boron and 
silicon. This means that EDS will detect signals from the coverslip for the elements boron 
and silicon. This is a significant dilemma considering that silicon is observed 1.73 kV and 
rubidium is observed at 1.69 kV (14). The significance of this dilemma is further 
exasperated considering that rubidium and silicon were observed to map in an almost 
identical fashion in EDS readings as seen in Figure 5. To overcome this challenge, a 
qualitative trial examining the effect of preparation surface was conducted. Isolated 
cardiomyocyte samples were prepared as seen in Figure 9. The sample of isolated 
cardiomyocytes was divided into two fractions. One fraction was prepared on typical 
Fisherbrand™ glass coverslips, and the second fraction was prepared on a specialized 
carbon stub. All other SEM/EDS parameters for the analysis were kept the same, and 
cells were observed in an internal view at 8,000x magnification for the presence rubidium 
within the cells as seen in Figure 23. Figure 23 shows that rubidium was detected 
similarly in a cell prepared on Fisherbrand™ glass coverslips and a cell prepared on the 
specialized carbon stub. 
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Figure 23:  Map of carbon at a magnification of x8,000 showing A) the carbon element-
print of a cell prepared on the surface of a Fisherbrand™ glass coverslip, B) the 
rubidium element-print of the cell in A, C) the carbon element-print of a cell prepared on 
a carbon-stub, and D) the rubidium element-print of the cell in C.   
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Appendix F  Cardiomyocyte Rubidium Levels in Experimental Trials 
 
  Linoleic Acid Trial 1 
  
Treatment Cell 
 
Rb (Weight 
 
Treatment Average  
Rubidium 1 1.07  
Rubidium 2 0.14  
Rubidium 3 0.41  
Rubidium 4 1.82  
Rubidium 5 1.75  
Rubidium 6 1.66  
Rubidium 7 1.9  
Rubidium 8 0.55  
Rubidium 9 0.65  
Rubidium 10 0.94 1.089 ± 0.206 
Ouabain 1 0.73  
Ouabain 2 0.52  
Ouabain 3 0.71  
Ouabain 4 1.31  
Ouabain 5 1.62  
Ouabain 6 0.41  
Ouabain 7 1.08  
Ouabain 8 1.02  
Ouabain 9 1.47  
Ouabain 10 1.37 1.024 ± 0.132 
Linoleic Acid 10-3 M 1 0  
Linoleic Acid 10-3 M 2 0  
Linoleic Acid 10-3 M 3 0.07  
Linoleic Acid 10-3 M 4 2.34  
Linoleic Acid 10-3 M 5 1.91  
Linoleic Acid 10-3 M 6 1.74  
Linoleic Acid 10-3 M 7 1.62  
Linoleic Acid 10-3 M 8 2.49  
Linoleic Acid 10-3 M 9 1.65  
Linoleic Acid 10-3 M 10 2.63 1.445 ± 0.329 
Linoleic Acid 10-6 M 1 1.04  
Linoleic Acid 10-6 M 2 2.67  
Linoleic Acid 10-6 M 3 2.41  
Linoleic Acid 10-6 M 4 2.56  
Linoleic Acid 10-6 M 5 1.22  
Linoleic Acid 10-6 M 6 0.31  
Linoleic Acid 10-6 M 7 0.41  
Linoleic Acid 10-6 M 8 0.65  
Linoleic Acid 10-6 M 9 0.17  
Linoleic Acid 10-6 M 10 1.2 1.264 ± 0.303 
62 
 
 
 
 
 
 
 
Linoleic Acid Trial 2 
Treatment Cell # Rb Weight % Treatment Rb % Average 
Rubidium 1 1.62  
Rubidium 2 2.95  
Rubidium 3 1.29  
Rubidium 4 1.79  
Rubidium 5 1.65  
Rubidium 6 2.54  
Rubidium 7 2.31  
Rubidium 8 1.67  
Rubidium 9 2.75  
Rubidium 10 2.39 2.096 ± 0.177 
Ouabain 1 1.1  
Ouabain 2 0.95  
Ouabain 3 0.98  
Ouabain 4 0.27  
Ouabain 5 0.39  
Ouabain 6 0.65  
Ouabain 7 0.39  
Ouabain 8 1.83  
Ouabain 9 0.73  
Ouabain 10 0 0.729 ± 0.165 
Linoleic Acid 10-3 M 1 0.35  
Linoleic Acid 10-3 M 2 1.85  
Linoleic Acid 10-3 M 3 0.46  
Linoleic Acid 10-3 M 4 0.94  
Linoleic Acid 10-3 M 5 0.62  
Linoleic Acid 10-3 M 6 1.03  
Linoleic Acid 10-3 M 7 0  
Linoleic Acid 10-3 M 8 0  
Linoleic Acid 10-3 M 9 0  
Linoleic Acid 10-3 M 10 0.03 0.528 ± 0.191 
Linoleic Acid 10-6 M 1 0.24  
Linoleic Acid 10-6 M 2 1.51  
Linoleic Acid 10-6 M 3 0.54  
Linoleic Acid 10-6 M 4 0.16  
Linoleic Acid 10-6 M 5 0.47  
Linoleic Acid 10-6 M 6 0  
Linoleic Acid 10-6 M 7 0.64  
Linoleic Acid 10-6 M 8 0.7  
Linoleic Acid 10-6 M 9 0.35  
Linoleic Acid 10-6 M 10 0 0.461 ± 0.140  
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Linoleic Acid Trial 3 
  Treatment Cell # Rb Weight % Treatment Rb % Average 
Rubidium 1 2.36  
Rubidium 2 0.88  
Rubidium 3 1.49  
Rubidium 4 0.84  
Rubidium 5 1.65  
Rubidium 6 1.69  
Rubidium 7 1.32  
Rubidium 8 1.28  
Rubidium 9 1.17  
Rubidium 10 2.06 1.474 ± 0.153 
Ouabain 1 0.38  
Ouabain 2 0.35  
Ouabain 3 0.45  
Ouabain 4 0.44  
Ouabain 5 1.05  
Ouabain 6 1.1  
Ouabain 7 0.85  
Ouabain 8 0.78  
Ouabain 9 0  
Ouabain 10 0.89 0.629 ± 0.113 
Linoleic Acid 10-3 M 1 0.81  
Linoleic Acid 10-3 M 2 0.23  
Linoleic Acid 10-3 M 3 2.49  
Linoleic Acid 10-3 M 4 0.65  
Linoleic Acid 10-3 M 5 0.66  
Linoleic Acid 10-3 M 6 1.79  
Linoleic Acid 10-3 M 7 0.92  
Linoleic Acid 10-3 M 8 1.62  
Linoleic Acid 10-3 M 9 0.76  
Linoleic Acid 10-3 M 10 1.73 1.166 ± 0.222 
Linoleic Acid 10-6 M 1 0.47  
Linoleic Acid 10-6 M 2 0.1  
Linoleic Acid 10-6 M 3 1.13  
Linoleic Acid 10-6 M 4 0.12  
Linoleic Acid 10-6 M 5 0.21  
Linoleic Acid 10-6 M 6 1.93  
Linoleic Acid 10-6 M 7 0  
Linoleic Acid 10-6 M 8 0  
Linoleic Acid 10-6 M 9 0.03  
Linoleic Acid 10-6 M 10 0.26 0.425 ± 0.199 
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Linoleic Acid Trial 4 
Treatment Cell # Rb Weight % Treatment Rb % Average 
Rubidium 1 2.25  
Rubidium 2 0.25  
Rubidium 3 0.87  
Rubidium 4 1.41  
Rubidium 5 1.25  
Rubidium 6 0.47  
Rubidium 7 0.17  
Rubidium 8 1.27  
Rubidium 9 0.65  
Rubidium 10 2.29 1.088 ± 0.239 
Ouabain 1 0  
Ouabain 2 0  
Ouabain 3 0  
Ouabain 4 0.89  
Ouabain 5 0.86  
Ouabain 6 1.52  
Ouabain 7 1.55  
Ouabain 8 0.54  
Ouabain 9 0.33  
Ouabain 10 0 0.569 ± 0.195 
Linoleic Acid 10-3 M 1 2.47  
Linoleic Acid 10-3 M 2 0  
Linoleic Acid 10-3 M 3 0  
Linoleic Acid 10-3 M 4 0  
Linoleic Acid 10-3 M 5 0.87  
Linoleic Acid 10-3 M 6 0.96  
Linoleic Acid 10-3 M 7 1.38  
Linoleic Acid 10-3 M 8 0.29  
Linoleic Acid 10-3 M 9 0.86  
Linoleic Acid 10-3 M 10 0 0.683 ± 0.254 
Linoleic Acid 10-6 M 1 0.22  
Linoleic Acid 10-6 M 2 0.2  
Linoleic Acid 10-6 M 3 1.53  
Linoleic Acid 10-6 M 4 0.06  
Linoleic Acid 10-6 M 5 0  
Linoleic Acid 10-6 M 6 0.24  
Linoleic Acid 10-6 M 7 0.01  
Linoleic Acid 10-6 M 8 2.1  
Linoleic Acid 10-6 M 9 0.85  
Linoleic Acid 10-6 M 10 0 0.521 ± 0.233 
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Linoleic Acid Trial 5 
  Treatment Cell # Rb Weight % Treatment Rb % Average 
Rubidium 1 0.54  
Rubidium 2 1.32  
Rubidium 3 1.52  
Rubidium 4 0.37  
Rubidium 5 0.2  
Rubidium 6 0  
Rubidium 7 0.18  
Rubidium 8 0.21  
Rubidium 9 2.48  
Rubidium 10 1.81 0.863 ± 0.270 
Ouabain 1 0  
Ouabain 2 0.69  
Ouabain 3 0.52  
Ouabain 4 0.89  
Ouabain 5 0.61  
Ouabain 6 0.49  
Ouabain 7 0.22  
Ouabain 8 0.44  
Ouabain 9 0.45  
Ouabain 10 2.48 0.679 ± 0.214 
Linoleic Acid 10-3 M 1 0  
Linoleic Acid 10-3 M 2 1.29  
Linoleic Acid 10-3 M 3 ______  
Linoleic Acid 10-3 M 4 ______  
Linoleic Acid 10-3 M 5 ______  
Linoleic Acid 10-3 M 6 ______  
Linoleic Acid 10-3 M 7 ______  
Linoleic Acid 10-3 M 8 ______  
Linoleic Acid 10-3 M 9 ______  
Linoleic Acid 10-3 M 10  ---- 
Linoleic Acid 10-6 M 1 1.5  
Linoleic Acid 10-6 M 2 1.92  
Linoleic Acid 10-6 M 3 1.11  
Linoleic Acid 10-6 M 4 0.37  
Linoleic Acid 10-6 M 5 1.48  
Linoleic Acid 10-6 M 6 0.66  
Linoleic Acid 10-6 M 7 2.11  
Linoleic Acid 10-6 M 8 2.45  
Linoleic Acid 10-6 M 9 1.62  
Linoleic Acid 10-6 M 10 2.14 1.536 ± 0.211 
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Linoleic Acid Trial 6 
Treatment Cell # Rb Weight % Treatment Rb % Average 
Rubidium 1 1.28  
Rubidium 2 1.57  
Rubidium 3 0.67  
Rubidium 4 1.02  
Rubidium 5 0.78  
Rubidium 6 1.03  
Rubidium 7 0.82  
Rubidium 8 1.12  
Rubidium 9 0.92  
Rubidium 10 2.31 1.152 ± 0.153 
Ouabain 1 0  
Ouabain 2 0  
Ouabain 3 0.17  
Ouabain 4 0.86  
Ouabain 5 0  
Ouabain 6 1.16  
Ouabain 7 0  
Ouabain 8 0.71  
Ouabain 9 0  
Ouabain 10 0 0.29 ± 0.140 
Linoleic Acid 10-3 M 1 0  
Linoleic Acid 10-3 M 2 2.39  
Linoleic Acid 10-3 M 3 0.9  
Linoleic Acid 10-3 M 4 0  
Linoleic Acid 10-3 M 5 0.72  
Linoleic Acid 10-3 M 6 1.03  
Linoleic Acid 10-3 M 7 1.14  
Linoleic Acid 10-3 M 8 0.05  
Linoleic Acid 10-3 M 9 0.51  
Linoleic Acid 10-3 M 10 0.36 0.710 ± 0.230 
Linoleic Acid 10-6 M 1 1.19  
Linoleic Acid 10-6 M 2 0  
Linoleic Acid 10-6 M 3 0.27  
Linoleic Acid 10-6 M 4 0  
Linoleic Acid 10-6 M 5 2.16  
Linoleic Acid 10-6 M 6 2.2  
Linoleic Acid 10-6 M 7 2.26  
Linoleic Acid 10-6 M 8 0  
Linoleic Acid 10-6 M 9 2.45  
Linoleic Acid 10-6 M 10 0.44 1.097 ± 0.338 
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Linoleic Acid Trial 7 
Treatment Cell 
 
Rb Weight % Treatment Rb % Average 
Rubidium 1 0.85  
Rubidium 2 1.35  
Rubidium 3 1.65  
Rubidium 4 1.53  
Rubidium 5 1.91  
Rubidium 6 1.54  
Rubidium 7 1.69  
Rubidium 8 1.34  
Rubidium 9 0.47  
Rubidium 10 0.79 1.312 ± 0.145 
Ouabain 1 0.3  
Ouabain 2 0.42  
Ouabain 3 0.24  
Ouabain 4 0.26  
Ouabain 5 0  
Ouabain 6 0.25  
Ouabain 7 0.22  
Ouabain 8 2.34  
Ouabain 9 1.48  
Ouabain 10 0.35 0.586 ± 0.232 
Linoleic Acid 10-3 M 1 0  
Linoleic Acid 10-3 M 2 0  
Linoleic Acid 10-3 M 3 2.28  
Linoleic Acid 10-3 M 4 2.2  
Linoleic Acid 10-3 M 5 0  
Linoleic Acid 10-3 M 6 2.15  
Linoleic Acid 10-3 M 7 0  
Linoleic Acid 10-3 M 8 0  
Linoleic Acid 10-3 M 9 1.89  
Linoleic Acid 10-3 M 10 0.68 0.92 ± 0.337 
Linoleic Acid 10-6 M 1 0.82  
Linoleic Acid 10-6 M 2 0.98  
Linoleic Acid 10-6 M 3 1.53  
Linoleic Acid 10-6 M 4 1.2  
Linoleic Acid 10-6 M 5 0.5  
Linoleic Acid 10-6 M 6 0.5  
Linoleic Acid 10-6 M 7 1.42  
Linoleic Acid 10-6 M 8 0.8  
Linoleic Acid 10-6 M 9 0.3  
Linoleic Acid 10-6 M 10 0.81 0.886 ± 0.128 
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Linoleic Acid Trial 8 
Treatment Cell 
 
Rb Weight % Treatment Rb % Average 
Rubidium 1 0.79  
Rubidium 2 1.44  
Rubidium 3 0.81  
Rubidium 4 1.23  
Rubidium 5 2.15  
Rubidium 6 0.22  
Rubidium 7 1.65  
Rubidium 8 0.97  
Rubidium 9 0.78  
Rubidium 10 0.78 1.082 ± 0.174 
Ouabain 1 0  
Ouabain 2 0.08  
Ouabain 3 1.88  
Ouabain 4 1.03  
Ouabain 5 1.22  
Ouabain 6 0.15  
Ouabain 7 1.68  
Ouabain 8 0.42  
Ouabain 9 0  
Ouabain 10 0.86 0.732 ± 0.223 
Linoleic Acid 10-3 M 1 0.66  
Linoleic Acid 10-3 M 2 0.1  
Linoleic Acid 10-3 M 3 0.42  
Linoleic Acid 10-3 M 4 0.53  
Linoleic Acid 10-3 M 5 1.37  
Linoleic Acid 10-3 M 6 1.77  
Linoleic Acid 10-3 M 7 0.31  
Linoleic Acid 10-3 M 8 1.77  
Linoleic Acid 10-3 M 9 0.34  
Linoleic Acid 10-3 M 10 1.93 0.92 ± 0.224 
Linoleic Acid 10-6 M 1 0.62  
Linoleic Acid 10-6 M 2 0  
Linoleic Acid 10-6 M 3 0  
Linoleic Acid 10-6 M 4 0  
Linoleic Acid 10-6 M 5 1.82  
Linoleic Acid 10-6 M 6 0.31  
Linoleic Acid 10-6 M 7 0.12  
Linoleic Acid 10-6 M 8 0.11  
Linoleic Acid 10-6 M 9 0  
Linoleic Acid 10-6 M 10 1.46 0.444 ± 0.210 
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Linoleic Acid Trial 9 
Treatment Cell 
 
Rb Weight % Treatment Rb % Average 
Rubidium 1 0.09  
Rubidium 2 1.26  
Rubidium 3 1.33  
Rubidium 4 0.99  
Rubidium 5 0.61  
Rubidium 6 2.27  
Rubidium 7 1.82  
Rubidium 8 1.05  
Rubidium 9 1.57  
Rubidium 10 1.37 1.236 ± 0.193 
Ouabain 1 1.89  
Ouabain 2 0.43  
Ouabain 3 2.01  
Ouabain 4 1.29  
Ouabain 5 1.42  
Ouabain 6 1.5  
Ouabain 7 0.55  
Ouabain 8 1.65  
Ouabain 9 0.18  
Ouabain 10 0.31 1.123 ± 0.218 
Linoleic Acid 10-3 M 1 0.27  
Linoleic Acid 10-3 M 2 0  
Linoleic Acid 10-3 M 3 1.14  
Linoleic Acid 10-3 M 4 1.39  
Linoleic Acid 10-3 M 5 0.76  
Linoleic Acid 10-3 M 6 0  
Linoleic Acid 10-3 M 7 1.19  
Linoleic Acid 10-3 M 8 0.52  
Linoleic Acid 10-3 M 9 1.35  
Linoleic Acid 10-3 M 10 0.39 0.701 ± 0.171 
Linoleic Acid 10-6 M 1 0  
Linoleic Acid 10-6 M 2 0.84  
Linoleic Acid 10-6 M 3 1.55  
Linoleic Acid 10-6 M 4 0  
Linoleic Acid 10-6 M 5 0.27  
Linoleic Acid 10-6 M 6 0.74  
Linoleic Acid 10-6 M 7 0.2  
Linoleic Acid 10-6 M 8 0.54  
Linoleic Acid 10-6 M 9 1.58  
Linoleic Acid 10-6 M 10 1.03 0.675 ± 0.184 
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Linoleic Acid Trial 10 
Treatment Cell 
 
Rb Weight % Treatment Rb % Average 
Rubidium 1 1.87  
Rubidium 2 1.23  
Rubidium 3 0.72  
Rubidium 4 2.13  
Rubidium 5 1.7  
Rubidium 6 1.91  
Rubidium 7 0.67  
Rubidium 8 1.75  
Rubidium 9 1.94  
Rubidium 10 0.07 1.399 ± 0.219 
Ouabain 1 0  
Ouabain 2 0  
Ouabain 3 0.24  
Ouabain 4 1.54  
Ouabain 5 0  
Ouabain 6 1.22  
Ouabain 7 0.72  
Ouabain 8 1.84  
Ouabain 9 0.68  
Ouabain 10 0.3 0.654 ± 0.213 
Linoleic Acid 10-3 M 1 0.75  
Linoleic Acid 10-3 M 2 0.05  
Linoleic Acid 10-3 M 3 0.6  
Linoleic Acid 10-3 M 4 1.69  
Linoleic Acid 10-3 M 5 1.43  
Linoleic Acid 10-3 M 6 2.04  
Linoleic Acid 10-3 M 7 0.76  
Linoleic Acid 10-3 M 8 0.38  
Linoleic Acid 10-3 M 9 1.58  
Linoleic Acid 10-3 M 10 1.31 1.059 ± 0.203 
Linoleic Acid 10-6 M 1 1.31  
Linoleic Acid 10-6 M 2 1.04  
Linoleic Acid 10-6 M 3 1.72  
Linoleic Acid 10-6 M 4 0.28  
Linoleic Acid 10-6 M 5 0  
Linoleic Acid 10-6 M 6 0.2  
Linoleic Acid 10-6 M 7 1.48  
Linoleic Acid 10-6 M 8 0.55  
Linoleic Acid 10-6 M 9 0.29  
Linoleic Acid 10-6 M 10 0.62 0.749 ± 0.189 
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Appendix G:  Formulation of Krebs Buffer 
 
Stock Solutions: 
Stock A 
-107 g of NaCl in 1 L ddH2O 
 
Stock B 
-5.96g of KCl 
-32.26g of NaHCO3 
-MgCl2*2H2O 
-dissolve contents in 1 L of ddH2O 
 
Stock C 
-CaCl2*2H2O 
-dissolve contents in 1 L of ddH2O 
 
Procedure: 
1. Mix 50 ml of each of Stock A, Stock B, and Stock C with 650 ml ddH2O. 
2. Add 1.9 g of 10mM HEPES 
3. Add 2 g of BSA 
4. Filter into a flask using paper filter. 
5. Adjust pH to 7.35 
6. Warm up to 37°C for usage, and store below 5°C. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
